An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Anetumab ravtansine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 13 Jan 2020 Status changed from active, no longer recruiting to completed.
- 14 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.